# KISS Study: Kinase Inhibition With Sprycel Start up

> **NCT03193281** · PHASE2 · UNKNOWN · sponsor: **University of Auckland, New Zealand** · enrollment: 91 (actual)

## Conditions studied

- Chronic Myeloid Leukemia

## Interventions

- **DRUG:** Dasatinib
- **DRUG:** Imatinib

## Key facts

- **NCT ID:** NCT03193281
- **Lead sponsor:** University of Auckland, New Zealand
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-07-17
- **Primary completion:** 2025-12-31
- **Final completion:** 2025-12-31
- **Target enrollment:** 91 (ACTUAL)
- **Last updated:** 2023-11-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03193281

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03193281, "KISS Study: Kinase Inhibition With Sprycel Start up". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03193281. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*